Treatment options for IgA nephropathy in adults: A proposal for evidence-based strategy

Nephrology Dialysis Transplantation

Volumn 19, Issue 8, 2004, Pages 1947-1951

  Laville, Maurice ^a   Alamartine, Eric ^b  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; ENALAPRIL; FISH OIL; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PLACEBO; POLYUNSATURATED FATTY ACID; PREDNISONE; STEROID; WARFARIN;

ADULT; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG MEGADOSE; EDITORIAL; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY PARENCHYMA; LOW DRUG DOSE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RISK FACTOR; TISSUE INJURY;

ADULT; DECISION SUPPORT TECHNIQUES; FISH OILS; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; GLUCOCORTICOIDS; HUMANS; PROGNOSIS; PROTEINURIA; TREATMENT OUTCOME;

EID: 4344599197     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh309     Document Type: Editorial

References (23)

1. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36: 227-237
2. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analysis. Am J Kidney Dis 1991; 18: 12-19
3. Radford M, Donadio JV, Bergstrahl E, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997; 8: 199-207
4. Szeto CC, Lai FM, To KF et al. The natural history of IgA nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 15: 497-498
5. Donadio JV, Bergstrahl EJ, Grande JP, Rademcher DM. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 2002; 17: 1197-1203
6. Levin A. The advantage of a uniform terminology and staging system for chronic kidney disease. Nephrol Dial Transplant 2003; 18: 1446-1451
7. Schena FP, Montenegro M, Scivittaro V. Meta-analysis of randomised controlled trials in patients with primary IgA nephropathy (Berger's disease). Nephrol Dial Transplant 1990; S1: 47-52
8. Strippoli G, Mano C, Schena F. An 'evidence-based' survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis 2003; 41: 1129-1139
9. Bennett WM, Walker RG, Kindkaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trials. Clin Nephrol 1989; 31: 129-131
10. Pettersson EE, Rekola S, Berglund L et al. Treatment of IgA nephropathy with omega-3-polyunsatured fatty acids: a prospective trial. Clin Nephrol 1994; 41: 183-190
11. Donadio JV, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994; 331: 1194-1199
12. Donadio JV, Grande JP, Begstrahl EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. J Am Soc Nephrol 1999; 10: 1772-1777
13. Donadio JV, Larson TS, Bergstrahl EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001; 12: 791-799
14. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997; 8: 1739-1744
15. Lai KN, Lai FM, HO CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26: 174-180
16. Shoji T, Nakanishi I, Suzuki A et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult with diffuse proliferative Iga nephropathy. Am J Kidney Dis 2000; 35: 194-201
17. Katafuchi R, Ikeda K, Mizusama T et al. Controlled prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003; 41: 972-983
18. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized controlled trial. J Am Soc Nephrol 2004; 15: 157-163
19. Praga M, Gutierez E, Gonzales E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled study. J Am Soc Nephrol 2003; 14: 1578-1583
20. Woo KY, Edmonson RPS, Yap HK et al. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis. Clin Nephrol 1987; 27: 56-64
21. Walker RG, Su SH, Owen JE, Kindkaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990; 34: 103-107
22. Beukhof J, Kardaun O, Schaafsma W et al. Toward individual pronosis of IgA nephropathy. Kidney Int 1986; 29: 549-546
23. Bartosik P, Lajoie G, Sugar L, Cattran D. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38: 728-735